Výsledky vyhledávání - "Edward G. McKeever"

The Effect of CYP3A4 Inhibition or Induction on the Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Healthy Volunteers

Autor: Swamy Yeleswaram, Naresh Punwani, Ryan F. McGee, Edward G. McKeever, Robert R. Landman, Thomas Emm, Xuejun Chen, Yvonne Lo, William V. Williams, Peggy Scherle, Jack G. Shi

Publikováno v: The Journal of Clinical Pharmacology. 52:809-818

Ruxolitinib, a selective Janus kinase (JAK) 1&2 inhibitor in development for the treatment of myeloproliferative neoplasms, is primarily metabolized by CYP3A4. The effects of inhibition or induction of CYP3A4 on single oral dose ruxolitinib pharmacok

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f22d1f4f44b4fa761054fa9b882c5533
https://doi.org/10.1177/0091270011405663

Zobrazit plný text záznamu

Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans

Autor: William V. Williams, Adam Shilling, Argyrios G. Arvanitis, Sharon Diamond, James D. Rodgers, Laurine G. Galya, Tai-Yuen Yue, Thomas Emm, Swamy Yeleswaram, Edward G. McKeever, Stacey Shepard, Mei Li, Frank M. Nedza, Naresh Punwani

Publikováno v: Drug metabolism and disposition: the biological fate of chemicals. 38(11)

The metabolism, excretion, and pharmacokinetics of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (INCB018424), a potent, selective inhibitor of Janus tyrosine kinase1/2 and the first investigational drug of its c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f52d1a57fc34e814839d71a024ca5518
https://pubmed.ncbi.nlm.nih.gov/20699411

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání